Raleigh, United States
Pathalys Pharma, founded in 2021, is a private, late-stage clinical biopharmaceutical company headquartered in the United States. The company's mission is articulated through its slogan: "Our mission is to improve the lives of patients through enhanced therapeutics to advance the management of CKD." This mission underscores their commitment to developing advanced therapeutics specifically for managing late-stage chronic kidney disease (CKD).
The company operates within the Biopharma and Biotechnology industries, and was established in collaboration with Catalys Pacific and DaVita. The focus is on creating multi-asset solutions for patients afflicted with end-stage renal disease, indicating a strategic concentration on addressing significant unmet medical needs.
Recently, Pathalys Pharma received a Debt Financing investment on 18 January 2023. This financial strategy suggests a judicious approach in fueling its development pipeline and enhancing its market position as it continues to seek transformative solutions for CKD management.
